Trial Profile
An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Chickenpox; Measles; Mumps; Pneumococcal infections; Rubella
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 16 Feb 2010 Primary endpoints identified as reported by ClinicalTrials.gov.
- 19 Feb 2009 Planned number of patients changed from 600 to 1027 as reported by ClinicalTrials.gov.
- 03 Aug 2008 Additional trial identifier V221-019 reported by ClinicalTrials.gov.